Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
  • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
  • A61K51/04—Organic compounds
  • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
  • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
  • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
  • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
  • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
  • G01N33/5082—Supracellular entities, e.g. tissue, organisms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
  • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Definitions

• the invention relates to proteins which are upregulated in injured or regenerating tissues, as well as to the DNA encoding these proteins.
• the invention further relates to therapeutic compositions and methods of treatment encompassing these proteins.
• a dynamic remodeling of tissue architecture occurs during development and during tissue repair after injury. To study this process, we have focused on a model of kidney injury caused by an ischemia-reperfusion insult.
• the kidney is able to repair damage to the proximal tubule epithelium through a complex series of events involving cell death, proliferation of surviving proximal tubule epithelial cells, formation of poorly differentiated regenerative epithelium over the denuded basement membrane, and differentiation of the regenerative epithelium to form a fully functional proximal tubule epithelial cells (Wallin et al., Lab. Invest. 66:474-484, 1992; Witzgall et al., Mol. Cell. Biol. 13:1933-1942, 1994; Ichimura et al., Am. J. Physiol. 269:F653-662, 1995; Thadhani et al., N.
• RDA representational difference analysis
• the invention generally provides Kidney Injury-related Molecules (each of which is henceforth called a "KIM") which are upregulated in renal tissue after injury to the kidney.
• KIM proteins and peptides of the invention as well as their agonists and antagonists, and their corresponding are useful in a variety of therapeutic interventions.
• the invention provides a purified and isolated DNA molecule having a nucleotide sequence set forth in SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6.
• the invention also includes the complementary strands of these sequences, DNA molecules which hybridize under stringent conditions to the aforementioned DNA molecules, and DNA molecules which, but for the degeneracy of the genetic code, would hybridize to any of the DNA molecules defined above.
• These DNA molecules may be recombinant, and may be operably linked to an expression control sequence.
• the invention further provides a vector comprising a purified and isolated DNA molecule having a nucleotide sequence set forth in SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6, or one of the other DNA molecules defined above.
• This vector may be a biologically functional plasmid or viral DNA vector.
• One embodiment of the invention provides a prokaryotic or eukaryotic host cell stably transformed or transfected by a vector comprising a DNA molecule of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6.
• a process for the production of a KIM polypeptide product encoded by a DNA molecule as described above; the process involves growing, under suitable culture conditions, prokaryotic or eukaryotic host cells transformed or transfected with the DNA molecule in a manner allowing expression of the DNA molecule, and recovering the polypeptide product of said expression.
• KIM proteins of the invention may have an amino acid sequence which comprises SEQ ID NO:3 , SEQ ID NO:5, or SEQ ID NO:7, or may be a variant of SEQ ID NO:3, SEQ ID NO:5 or SEQ ID NO:7, or a purified and isolated protein encoded by the DNA of SEQ ID NO: 1 , SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6. These proteins can be provided substantially free of other human proteins.
• the invention further includes variants of these proteins, such as soluble variants or fusion proteins.
• KIM fusion proteins of the invention may comprise an immunoglobulin, a toxin, an imageable compound or a radionuclide.
• the invention also provides a specific monoclonal antibody to the KIM proteins described above.
• the anti-KIM antibody may be associated with a toxin, imageable compound or radionuclide. Further taught is a hybridoma cell line which produces such a specific antibody.
• Pharmaceutical compositions are also within the scope of the invention.
• a pharmaceutical composition of the invention may comprise a therapeutically effective amount of a KIM protein or anti-KIM antibody of the invention, along with a pharmacologically acceptable carrier. Diagnostic methods are within the invention, such as assessing the presence or course of resolution of renal injury by measuring the concentration of KIM in urine, serum, or urine sediment of patients who have or who are at risk of developing renal disease.
• Methods of treatment of the invention include treating patients with therapeutically effective amounts of KIM, KIM variants, KIM analogs, KIM fusion proteins, KIM agonists, and antibodies to KIM or to KIM ligands.
• Other therapeutic compounds of the invention include KIM ligands, anti-KIM antibodies, and fusions proteins of KIM ligands. These compounds can be useful in therapeutic methods which either stimulate or inhibit cellular responses that are dependent on KIM function.
• Further methods of the invention inhibit the growth of KIM-expressing tumor cells by contacting the cells with a fusion protein of a KIM ligand and either a toxin or radionuclide, or with an anti-KIM antibody conjugated to a toxin or to a radionuclide.
• growth of tumor cells which express KIM ligand may be inhibited by contacting the cells with a fusion protein of a KIM and either a toxin or radionuclide, or with an anti-KIM ligand antibody conjugated to a toxin or to a radionuclide.
• the invention also encompasses methods of gene therapy.
• These include a method of treating a subject with a renal disorder, a method of promoting growth of new tissue in a subject, and a method of promoting survival of damaged tissue in a subject, comprising administering to the subject a vector which includes DNA comprising the nucleotide sequence of SEQ ID NO: 1 , SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6.
• the compounds of the invention are also useful for imaging tissues, either in vitro or in vivo.
• One such method involves targeting an imageable compound to a cell expressing a protein of SEQ ID NO:3, SEQ ID NO:5 or SEQ ID NO:7, comprising contacting the cell with either a monoclonal antibody of the invention or a fusion protein comprising a protein as described above, fused to an imageable compound.
• the cell is within a subject, and the protein or the monoclonal antibody is administered to the subject.
• the invention also includes diagnostic methods, such as a method of identifying damage or regeneration of renal cells in a subject, comprising comparing the level of expression of either SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6 in renal cells of the subject to a control level of expression of the sequence in control renal cells.
• Another method of the invention includes identifying upregulation of SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6 in cells comprising contacting the cells with an antisense probe and measuring hybridization to RNA within the cell.
• a further embodiment of the diagnostic methods of the invention includes assessing the presence or concentration of a molecule of the invention either in urine, serum, or other body fluids, or in urine sediment or tissue samples.
• the measured injury-related molecule can be correlated with the presence, extent or course of a pathologic process. This correlation can also be used to assess the efficacy of a therapeutic regime.
• FIGURE 1 is the nucleotide sequence of rat clone cDNA 3-2, with putative protein reading frame of615 to l535.
• FIGURE 2 is a listing of the cDNA sequence of rat clone 1-7, with putative protein reading frame of 145 to 1065.
• FIGURE 3 is a listing of the cDNA sequence of rat clone 4-7, with putative protein reading frame of 107 to 1822.
• FIGURE 4 is a listing of the cDNA and deduced amino acid sequences of human clone HI3-10- 85, with putative protein reading frame of 1 to 1002.
• the upper line of the listing is the cDNA sequence (SEQ ID NO:6), and the lower line is the deduced amino acid sequence (SEQ ID NO:6)
• FIGURE 5 is a BESTFIT comparison of the nucleotide sequence of human clone HI3- 10-85 with that of rat clone 3-2.
• RDA representational difference analysis
• SEQ ID NO:5 amino acid sequence encoded by 4-7 cDNA insert
• SEQ ID NO:6 nucleotide sequence of human cDNA clone H13-10-85
• KIM protein is a protein encoded by mRNA which is selectively upregulated following injury to a kidney.
• One group of KIM proteins of interest includes those coded for by mRNA which is selectively upregulated at any time within one week following any insult which results in injury to renal tissue. Examples of times at which such upregulation might be identified include 10 hours, 24 hours, 48 hours or 96 hours following an insult. Examples of types of insults include those resulting in ischemic, toxic or other types of injury.
• KIM agonist is a molecule which can specifically trigger a cellular response normally triggered by the interaction of KIM with a KIM ligand.
• a KIM agonist can be a KIM variant, or a specific antibody to KIM, or a soluble form of the KIM ligand.
• KIM antagonist is a molecule which can specifically associate with a KIM ligand or KIM, thereby blocking or otherwise inhibiting KIM binding to the KIM ligand.
• the antagonist binding blocks or inhibits cellular responses which would otherwise be triggered by ligation of the KIM ligand with KIM or with a KIM agonist.
• KIM antagonists include certain KIM variants, KIM fusion proteins and specific antibodies to a KIM ligand or KIM.
• a "KIM ligand” is any molecule which noncovalently and specifically binds to a KIM protein.
• a ligand can be a protein, peptide, steroid, antibody, amino acid derivative, or other type molecule, in any form, including naturally-occurring, recombinantly produced, or otherwise synthetic.
• a KIM ligand can be in any form, including soluble, membrane-bound, or part of a fusion construct with immunoglobulin, fatty acid, or other moieties.
• the KIM ligand may be an integrin.
• a membrane-bound KIM ligand can act as a receptor which, when bound to or associated with KIM, triggers a cellular response.
• KIM may associate with more than a single KIM ligand, or may associate with a KIM ligand as part of a complex with one or more other molecules or cofactors.
• the KIM may associate and react with KIM ligand which is bound to the same cell as the KIM, or it may associate and react with KIM ligand be bound to a second cell.
• the KIM ligation occurs between molecules bound to different cells, the two cells may be the same or different with respect to cellular type or origin, phenotypic or metabolic condition, or type or degree of cellular response (e.g., growth, differentiation or apoptosis) to a given stimulus.
• KIM ligation refers to the contact and binding of KIM with a KIM ligand.
• alignment of sequences is meant the positioning of one sequence, either nucleotide or amino acid, with that of another, to allow a comparison of the sequence of relevant portions of one with that of the other.
• An example of one method of diis procedure is given in Needleman et al. (J. Mol. Biol. 48:443-453, 1970). The method may be implemented conveniently by computer programs such as the Align program (DNAstar, Inc.).
• homologous or functionally equivalent sequences include functionally equivalent arrangements of the cysteine residues within the conserved cysteine skeleton, including amino acid insertions or deletions which alter the linear arrangement of these cysteines, but do not materially impair their relationship in the folded structure of the protein. Therefore, internal gaps and amino acid insertions in the candidate sequence are ignored for purposes of calculating the level of amino acid sequence homology or identity between the candidate and reference sequences.
• One characteristic frequently used in establishing the homology of proteins is the similarity of the number and location of the cysteine residues between one protein and another.
• Antisense DNA refers to the sequence of chromosomal DNA that is transcribed.
• an “antisense probe” is a probe which comprises at least a portion of the antisense DNA for a nucleic acid portion of interest.
• cloning is meant the use of in vitro recombination techniques to insert a particular gene or other DNA sequence into a vector molecule.
• in vitro recombination techniques to insert a particular gene or other DNA sequence into a vector molecule.
• it is necessary to employ methods for generating DNA fragments, for joining the fragments to vector molecules, for introducing the composite DNA molecule into a host cell in which it can replicate, and for selecting the clone having the target gene from amongst the recipient host cells.
• cDNA is meant complementary or copy DNA produced from an RNA template by the action of RNA-dependent DNA polymerase (reverse transcriptase).
• a “cDNA clone” means a duplex DNA sequence complementary to an RNA molecule of interest, carried in a cloning vector.
• cDNA library is meant a collection of recombinant DNA molecules containing cDNA inserts which together comprise a representation of the mRNA molecules present in an entire organism or tissue, depending on the source of the RNA templates.
• a cDNA library may be prepared by methods known to those of skill, and described, for example, in Maniatis et al., Molecular Cloning: A Laboratory Manual, supra.
• RNA is first isolated from the cells of an organism from whose genome it is desired to clone a particular gene. Preferred for the purposes of the present invention are mammalian, and particularly human, cell lines.
• RNA may be isolated from a tumor cell, derived from an animal tumor, and preferably from a human tumor.
• a library may be prepared from, for example, a human adrenal tumor, but any tumor may be used.
• DNA polymorphism refers to the condition in which two or more different nucleotide sequences can exist at a particular site in DNA.
• “Expression vector” includes vectors which are capable of expressing DNA sequences contained therein, i.e., the coding sequences are operably linked to other sequences capable of effecting their expression. It is implied, although not always explicitly stated, that these expression vectors must be replicable in the host organisms either as episomes or as an integral part of the chromosomal DNA.
• a useful, but not a necessary, element of an effective expression vector is a marker encoding sequence, which is a sequence encoding a protein which results in a phenotypic property (such as tetracycline resistance) of the cells containing the protein which permits those cells to be readily identified.
• expression vector is given a functional definition, and any DNA sequence which is capable of effecting expression of a specified contained DNA code is included in this term, as it is applied to the specified sequence.
• vectors are frequently in the form of plasmids, thus “plasmid” and “expression vector” are often used interchangeably.
• the invention is intended to include such other forms of expression vectors which serve equivalent functions and which may, from time to time become known in the art.
• a “fragment” of a molecule such as any of the antigens of the present invention is meant to refer to any polypeptide subset of the molecule.
• a “variant” of such molecules is meant to refer to a naturally occurring molecule substantially similar to either the entire molecule, or a fragment thereof.
• An “analog” of a molecule is meant to refer to a non-natural molecule substantially similar to either the entire molecule or a fragment thereof.
• the term “gene” means a polynucleotide sequence encoding a peptide.
• label refers to a molecular moiety capable of detection including, by way of example, without limitation, radioactive isotopes, enzymes, luminescent agents, and dyes.
• probe refers to a ligand of known qualities capable of selectively binding to a target antiligand.
• probe refers to a strand of nucleic acid having a base sequence complementary to a target strand.
• Recombinant host cells refers to cells which have been transformed with vectors constructed using recombinant DNA techniques. As defined herein, the antibody or modification thereof produced by a recombinant host cell is by virtue of this transformation, rather than in such lesser amounts, or more commonly, in such less than detectable amounts, as would be produced by the untransformed host.
• substantially pure any protein of the present invention, or any gene encoding any such protein, which is essentially free of other proteins or genes, respectively, or of other contaminants with which it might normally be found in nature, and as such exists in a form not found in nature.
• a molecule is said to be "substantially similar” to another molecule if the sequence of amino acids in both molecules is substantially the same, and if both molecules possess a similar biological activity. Thus, provided that two molecules possess a similar activity, they are considered variants as that term is used herein even if one of the molecules contains additional amino acid residues not found in the other, or if the sequence of amino acid residues is not identical.
• a molecule is said to be a "chemical derivative" of another molecule when it contains additional chemical moieties not normally a part of the molecule. Such moieties may improve the molecule's solubility, absorption, biological half life, etc.
• the moieties may alternatively decrease the toxicity of the molecule, eliminate or attenuate any undesirable side effect of the molecule, etc. Moieties capable of mediating such effects are disclosed, for example, in Remington's Pharmaceutical Sciences. 16th ed.. Mack Publishing Co., Easton, Penn. (1980).
• vector is meant a DNA molecule, derived from a plasmid or bacteriophage, into which fragments of DNA may be inserted or cloned.
• a vector will contain one or more unique restriction sites, and may be capable of autonomous replication in a defined host or vehicle organism such that the cloned sequence is reproducible.
• the invention includes the cDNA of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6, as well as sequences which include the sequence of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6, and derivatives of these sequences.
• the invention also includes vectors, liposomes and other carrier vehicles which encompass these sequence or derivatives of them.
• the invention further includes proteins transcribed from SEQ ID NO: 1 ,
• One embodiment of the invention includes soluble variants of a KIM protein that is usually synthesized as a membrane associated protein, and which is upregulated after injury.
• Soluble variants lack at least a portion of the transmembrane or intra-membrane section of a native KIM protein. In some examples, the soluble variant lacks the entire transmembrane or intra-membrane section of a native KIM protein.
• Soluble variants include fusion proteins which encompass derivatives of KIM proteins that lack at least a portion of the transmembrane or intra- membrane section of a native KIM protein. All types of KIM fusion proteins are included, particularly those which incorporate his-tag, Ig-tag, and myc-tag forms of the molecule. These KIM fusions may have characteristics which are therapeutically advantageous, such as the increased half-life conferred by the Ig-tag. Also included are fusion proteins which incorporate portions of selected domains of the KIM protein.
• Variants can differ from naturally occurring KIM protein in amino acid sequence or in ways that do not involve sequence, or both. Variants in amino acid sequence are produced when one or more amino acids in naturally occurring KIM protein is substituted with a different natural amino acid, an amino acid derivative or non-native amino acid. Particularly preferred variants include naturally occurring KIM protein, or biologically active fragments of naturally occurring KIM protein, whose sequences differ from the wild type sequence by one or more conservative amino acid substitutions, which typically have minimal influence on the secondary structure and hydrophobic nature of the protein or peptide. Variants may also have sequences which differ by one or more non-conservative amino acid substitutions, deletions or insertions which do not abolish the KIM protein biological activity.
• Conservative substitutions typically include the substitution of one amino acid for another with similar characteristics such as substitutions within the following groups: valine, glycine; glycine, alanine; valine, isoleucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.
• the non-polar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine.
• the polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine and glutamine.
• the positively charged (basic) amino acids include arginine, lysine and histidine.
• the negatively charged (acidic) amino acids include aspartic acid and glutamic acid.
• variants within the invention are those with modifications which increase peptide stability.
• Such variants may contain, for example, one or more non-peptide bonds (which replace the peptide bonds) in the peptide sequence.
• substitutions that may be expected to induce changes in the functional properties of KIM polypeptides are those in which: (I) a hydrophilic residue, e.g., serine or threonine, is substituted by a hydrophobic residue, e.g., leucine, isoleucine, phenylalanine, or alanine; (ii) a cysteine residue is substituted for (or by) any other residue; (iii) a residue having an electropositive side chain, e.g., lysine, arginine or histidine, is substituted for (or by) a residue having an electronegative charge, e.g., glutamic acid or aspartic acid; or (iv) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) one not having such a side chain, e.g., glycine.
• a hydrophilic residue e.g., serine or
• the peptides of this invention may also be modified by various changes such as insertions, deletions and substitutions, either conservative or nonconservative where such changes might provide for certain advantages in their use.
• Splice variants are specifically included in the invention.
• variants with amino acid substitutions which are less conservative may also result in desired derivatives, e.g., by causing changes in charge, conformation and other biological properties.
• substitutions would include for example, substitution of hydrophilic residue for a hydrophobic residue, substitution of a cysteine or proline for another residue, substitution of a residue having a small side chain for a residue having a bulky side chain or substitution of a residue having a net positive charge for a residue having a net negative charge.
• the derivatives may be readily assayed according to the methods disclosed herein to determine the presence or absence of the desired characteristics.
• Variants within the scope of the invention include proteins and peptides with amino acid sequences having at least eighty percent homology with a KIM protein. More preferably the sequence homology is at least ninety percent, or at least ninety-five percent. For the purposes of determining homology the length of comparison sequences will generally be at least 8 amino acid residues, usually at least 20 amino acid residues.
• Variants of the compounds of the invention also includes any protein which 1) has an amino acid sequence which is at least forty percent homologous to a KIM protein of the invention, and also which 2) after being placed in an optimal alignment with the KIM sequence (as depicted in Figure 5 for human and for rat KIM-1) has at least 80% of its cysteine residues aligned with cysteines in the KIM protein of the invention.
• Non- sequence modifications may include, for example, in vivo or in vitro chemical derivatization of portions of naturally occurring KIM protein, as well as changes in acetylation, methylation, phosphorylation, carboxylation or glycosylation. Also included within the invention are agents which specifically bind to the protein, or a fragment of the protein (SEQ ID NO:3, 5 or 7).
• agents include ligands and antibodies (including monoclonal, single chain, double chain, Fab fragments, and others, whether native, human, humanized, primatized, or chimeric). Additional descriptions of these categories of agents are in PCT application 95/16709, the specification of which is herein incorporated by reference.
• Ischemic injured rat kidneys are generated as described by Witzgall et al. (J. Clin Invest. 93: 2175-2188, 1994). Briefly, the renal artery and vein from one kidney of an adult Sprague- Dawley rat are clamped for 40 minutes and then reperfused. Injured kidneys are harvested from the rats at 24 hours and at 48 hours after reperfusion. Kidneys from sham-operated, normal adult Sprague-Dawley rats are also harvested.
• RNA is prepared from the organs based on the protocol by Glisin et al. (Biochemistry 13: 2633, 1974). Briefly, the harvested organs are placed immediately into GNC buffer (4M guanidine thiocyanate, 0.5% SDS, 25mM sodium citrate, 0.1% Sigma anti foam) and disrupted on ice with a polytron. Cell debris is removed with a low speed spin in a clinical centrifuge and the supernatant fluid is placed on a 5.7 M CsCl, 25mM sodium acetate, ImM EDTA cushion. RNA is pelleted through the cushion in a SW40Ti rotor at 22K for 15hrs.
• GNC buffer M guanidine thiocyanate, 0.5% SDS, 25mM sodium citrate, 0.1% Sigma anti foam
• RNA is resuspended in sterile DEPC- treated water, precipitated twice with 1/10 volume 3M sodium acetate and 2.5 volumes of EtOH.
• Poly A+ RNA is isolated using an mRNA purification kit (Pharmacia, catalog No.27-9258-02).
• Double stranded cDNA is synthesized from sham-operated and from 48hr post-ischemic kidney poly A+ RNA using Gibco BRL "Superscript ChoiceTM System cDNA Synthesis Kit” , catalog No. 18090.
• First strand is synthesized by priming with oligo dT and using Superscript IITM reverse transcriptase.
• Second strand is generated using E. coli DNA polymerase I and RNase H followed by T4 DNA polymerase using BRL recommended conditions.
• RDA analysis is performed essentially as described by Hubank and Schatz (Nucleic Acid
• Hybridization of tester and driver amplicons followed by selective amplification are performed three times to generate Differential Product One (DPI), Two (DP2) and Three (DP3).
• DPI Differential Product One
• DP2 and DP3 products are also generated as described by Hubank and Schatz (id.), except that the drive ⁇ tester ratios are changed to 5,333:1 for DP2 and to 40,000 :1 or 4,000:1 for DP3.
• RDA product 1-7 (252bp) when the DP3 was generated using a ratio of 40,000:1
• product RDA 3-2 (445bp) and 4-7 (483bp) when the DP3 was generated using a ratio of 4,000: 1.
• the DNA fragments are subcloned using the Pharmacia SurecloneTM kit (catalog No. 27-9300-01) to repair the ends of the PCR fragments with Klenow enzyme and to facilitate blunt end ligation of the fragments into the pUC18 vector.
• RNA (2.5 ⁇ g) from rat normal adult kidney (sham operated) , from 48hr post ⁇ ischemic injured adult kidney, and from day 18 embryonic kidney is electrophoresed and Northern blotted (Cate, Cell 45:685, 1986) to a GeneScreenTM membrane (Dupont).
• Hybridization in PSB buffer 50mM Tris 7.5, IM NaCl , 0.1% Na pyrophosphate, 0.2% PVP, 0.2% Ficoll, 0.2% BSA, 1% SDS), containing 10% dextran sulphate and lOO ⁇ g/ml tRNA, is performed at 65C using three different probes: 1-7 RDA product, 3-2 RDA product and 4-7 RDA product.
• RDA products 1-7, 3-2 and 4-7 hybridize to mRNAs present in all three samples, but most intensely to mRNAs in the 48hr post-ischemic kidney RNA samples.
• a Northern blot analysis of adult rat tissues indicates that the 1-7 gene is expressed at very low levels in normal adult kidney, testis, spleen and lung.
• the 3-2 gene is expressed in liver, kidney, spleen, and brain.
• the 4-7 gene is expressed in spleen, kidney, lung, testis, heart , brain, liver, and skeletal muscle.
• the presence of different sized mRNAs in some tissues in the 1-7 and 3-2 blot indicates that the primary transcription product of the 1-7 gene and of the 3-2 gene may undergo alternate splicing and/or polyadenylation.
• a cDNA library is generated from 4 ⁇ g of polyA+ RNA from 48hr post-ischemic injured kidney using reagents from BRL Superscript ChoiceTM System for cDNA synthesis, and StratageneTM Lambda ZapII cloning kit (catalog No. 236201), according to protocols recommended by the manufacturers. 10 5 clones are screened with the 3-2 RDA product as a probe (random primed labeled as described above). Eight positive clones are selected and four are randomly chosen for secondary analysis to obtain pure phage plaques. After tertiary screening, four pure phage clones are isolated. Cloned inserts from the phage are isolated by in vivo excision procedure according to StratageneTM Lambda Zap II kit.
• cDNA clone 3-2 The largest insert, of approximately 2.6 kb (referred to as cDNA clone 3-2), is subjected to DNA sequencing.
• the sequence of the insert (SEQ ID NO: 1 ) is shown in Figure 1.
• cDNA clone 3-2 E. coli K-12, SOLR/p3-2#5-l
• the sequence of cDNA clone 3-2 is identical to that of clone 1 -7 cDNA (SEQ ID NO: 2), except that nucleotides 136-605 of SEQ ID NO:l represent an insertion.
• SEQ ID NO:2 represents a splice variant form of SEQ ID NO: 1.
• the clone for 1-7 (E. coli K-12, SOLR/pl-7#3-l) has been deposited as ATCC No. 98060.
• the sequence of 3-2 cDNA ( Figure 1; SEQ ID NO:l) contains an open reading frame of 307 amino acids ( Figure 1; SEQ ID NO:3). A signal sequence of 21 amino acids is inferred from Von Heijne analysis (Von Heijne et al., Nucl. Acid Res. 14:14683 (1986)), and a transmembrane region spanning approximately aa 235-257 indicates that the 3-2 product is a cell surface protein.
• the sequence of 1-7 cDNA ( Figure 2; SEQ ID NO:2) contains an open reading frame of 307 amino acids, which is identical to the open reading frame contained in the 3-2 cDNA (SEQ ID NO: 3) .
• the sequence of 4-7 cDNA ( Figure 3; SEQ ID NO:4) contains an open reading frame of 572 amino acids (SEQ ID NO:5). A transmembrane region is located at approximately amino acids 501-521.
• kidneys are perfusion fixed with 4% paraformaldehyde in PBS. Kidneys are further fixed overnight at 4C and processed. Paraffin sections are deparaffinized and rehydrated, fixed with 4% paraformaldehyde in PBS, digested with proteinase K, refixed, then acetylated with acetic anhydride in triethanolamine buffer. Sections are then dehydrated and hybridized with 32 P-labeled riboprobes at 55 °C overnight, with 33P-labeled riboprobes generated from 3-2 RDA or 1-7 RDA products subcloned into BamHI site of pGEM-11Z.
• a 32 P-labeled DNA probe comprising nucleotides 546-969 of the insert of clone 3-2 shown in Figure 1 is generated and used to screen a human embryonic liver lambda gtlO cDNA library (Clontech Catalog #HL5003a). 1 XI 0 6 plaques are screened in duplicate using standard conditions as described above but temperature for screening was 55C. For the high stringency wash, the filters are washed in 2X SSC at 55C. Fifty positive phage are identified and plaque purified, and DNA is prepared. The phage DNAs are subjected to Southern analysis using the same probe as above. The Southern blot filter is subjected to a final wash with 0.5X SSC at 55C. Two clones are identified as positive.
• the insert of clone HI 3-10-85 is sequenced and a region is found that encodes a protein with a high level of identity to the 3-2 protein shown in Figure 3.
• the human 3-2 related protein is 43.8% identical and 59.1% similar to the rat 3-2 protein. Both contain IgG, mucin, transmembrane, and cytoplasmic domains. The six cysteines within the IgG domains of both proteins are conserved.
• a fusion protein of the extracellular domain of KIM and the Fc region of immunoglobulin (Ig) is a useful tool for the study of the molecular and cellular biology of the injured/regenerating kidney and as a therapeutic molecule.
• a fragment of the extracellular domain of KIM-1 cDNA was amplified by PCR and cloned in the Biogen expression vector, pCA125, for transient expression in COS cells.
• the expression vector pCA125 produces a fusion protein which has a structure from gene cloned at N-terminus and a human Ig Fc region at the C- terminus.
• COS cells were transfected with the plasmids SJR 103 or 104; these plasmids express a fusion protein which contains the human KIM sequences 263-1147 (SEQ ID NO:6; SJR 103) or rat KIM sequences 599- 1319 (SEQ ID NO: 1 ; SJR 104) of the extracellular domain fused to human Ig Fc region.
• the cells were grown in 10% FBS in DMEM in the cell factory (Nunc, Naperville, Il).Two to three days post-transfection, medium was harvested, concentrated using Amicon concentrator, and fusion protein was purified using Protein-A Sepharose column. After purification, purity of fusion protein was evaluated by SDS-PAGE.
• Anti-KIM antibodies of the invention which specifically bind to the protein of SEQ ID NO:3, SEQ ID NO: 5 or SEQ ID NO: 7 or a fragment thereof, are useful in several diagnostic methods. These agents may be labeled with detectable markers, such as fluoroscopically or radiographically opaque substances, and administered to a subject to allow imaging of tissues which express KIM protein. The agents may also be bound to substances, such as horseradish peroxidase, which can be used as immunocytochemical stains to allow visualization of areas of KIM protein-positive cells on histological sections. A specific antibody could be used alone in this manner, and sites where it is bound can be visualized in a sandwich assay using an anti- immunoglobulin antibody which is itself bound to a detectable marker.
• detectable markers such as fluoroscopically or radiographically opaque substances
• the agents may also be bound to substances, such as horseradish peroxidase, which can be used as immunocytochemical stains to allow visualization of areas of KIM protein-positive cells on histological sections.
• the invention includes a method of diagnosing renal injury, or of monitoring a process of renal repair, by measuring the concentration of KIM or of KIM fragments in the urine, plasma or serum of a patient.
• KIM can be measured in urine sediment, in particular in cellular debris in the urine sediment. Casts of renal tubule cells, which may be present in urine sediment from patients with ongoing renal disease, may contain elevated levels of KIM protein and mRNA.
• Specific antibodies to KIM protein may also be bound to solid supports, such as beads or dishes, and used to remove the ligand from a solution, either for measurement, or for purification and characterization of the protein or its attributes (such as posttranslational modifications). Such characterization of a patient's KIM protein might be useful in identifying deleterious mutants or processing defects which interfere with KIM function and are associated with abnormal patient phenotypes. Each of these techniques is routine to those of skill in the immunological arts.
• Additional imaging methods utilize KIM or KIM fragments, fused to imageable moieties, for diagnostic imaging of tissues that express KIM ligands, particularly tumors.
• kidney homogenates of contralateral and postischemic kidneys 24 and 48 hours following a 40 minute clamping of the renal artery and vein of a single kidney for each rat The kidney homogenate was assessed for the presence of KIM-1 protein.
• Western blot analysis identifies three proteins detected by two different antibodies after ischemic injury, which are not detectable in homogenates from contralateral kidneys which were not exposed to ischemic injury. The apparent molecular weights of the bands are approximately 40kDa, 50kDa and 70-80kDa.
• the three protein species detected by western blotting could represent glycosylated forms of the same protein given the presence of potential N and O linked glycosylation sites.
• the KIM-1 sequence presents two putative sites for N-glycosylation and a mucin domain where O-glycosylation could cover the polypeptide chain.
• the three KIM-1 bands detected in postischemic kidney could correspond to glycosylation variants of the same core protein.
• De-N- glycosylation with PNGase F resulted in a shift of all three bands to a lower molecular weight, corresponding to a loss of about 3kDa, indicating that all three proteins are N-glycosylated. Differences in O-glycosylation might explain the differences in sizes of these three bands.
• the therapeutic methods of the invention involve selectively promoting or inhibiting cellular responses that are dependent on KIM ligation.
• the signal transduction may occur in the KIM-expressing cell, in the KIM ligand-expressing cell, or in both.
• KIM ligation-triggered response in a KIM ligand-expressing cell may be generated by contacting the cell with exogenous KIM, KIM fusion proteins or activating antibodies against KIM ligand, either in vitro or in vivo.
• responses of the KIM ligand-expressing cell that would otherwise be triggered by endogenous KIM could be blocked by contacting the KIM ligand-expressing cell with a KIM ligand antagonist (e.g., an antagonist antibody that binds to KIM ligand), or by contacting the endogenous KIM with an anti-KIM antibody or other KIM- binding molecule which prevents the effective ligation of KIM with a KIM ligand.
• a KIM ligand antagonist e.g., an antagonist antibody that binds to KIM ligand
• KIM ligation-triggered response in a KIM-expressing cell may be generated by contacting the cell with a soluble KIM ligand, or certain anti-KIM activating antibodies.
• responses of the KIM-expressing cell that would otherwise be triggered by interaction with endogenous KIM ligand could be blocked by contacting the KIM-expressing cell with an antagonist to KIM (e.g.., a blocking antibody that binds to KIM in a manner that prevents effective, signal-generating KIM ligation), or by contacting the endogenous KIM ligand with an anti-KIM ligand antibody or other KIM ligand- binding molecule which prevents the effective ligation of KIM with the KIM ligand.
• an antagonist to KIM e.g., a blocking antibody that binds to KIM in a manner that prevents effective, signal-generating KIM ligation
• an anti-KIM ligand antibody or other KIM ligand- binding molecule which prevents the effective ligation of KIM with the KIM ligand.
• One therapeutic use of the KIM-related compounds of the invention is for treating a subject with renal disease, promoting growth of new tissue in a subject, or promoting survival of damaged tissue in a subject, and includes the step of administering to the subject a therapeutically effective amount of a KIM protein of the invention, or of a pharmaceutical composition which includes a protein of the invention.
• the protein used in these methods may be a fragment of a full-length KIM protein, a soluble KIM ligand protein or fusion fragment, or a KIM agonist.
• These methods may also be practiced by administering to the subject a therapeutically effective amount of an agonist antibody of the invention, or a pharmaceutical composition which includes an agonist antibody of the invention.
• a KIM protein may be administered concurrently with a therapeutically effective amount of a second compound which exerts a medically desirable adjunct effect.
• tissues of interest for these methods may include any tissue, preferred tissues include renal tissue, liver, neural tissue, heart, stomach, small intestine, spinal cord, or lung.
• Particular renal conditions which may be beneficially treated with the compounds of the invention include acute renal failure, acute nephritis, chronic renal failure, nephrotic syndrome, renal tubule defects, kidney transplants, toxic injury, hypoxic injury, and trauma.
• Renal tubule defects include those of either hereditary or acquired nature, such as polycystic renal disease, medullary cystic disease, and medullary sponge kidney.
• a therapeutic intervention for inhibiting growth of undesirable, KIM ligand-expressing tissue in a subject includes the step of administering to the subject a therapeutically effective amount of a KIM antagonist (e.g.., an antagonist antibody that binds to KIM ligand), or by administering a therapeutically effective amount of an anti-KIM antibody or other KIM-binding molecule which blocks KIM binding to the KIM ligand-expressing tissue.
• a KIM antagonist e.g.., an antagonist antibody that binds to KIM ligand
• the KIM antagonist or anti-KIM antibody may be used therapeutically to inhibit or block growth of tumors which depend on KIM protein for growth.
• Other methods of the invention include killing KIM ligand-expressing tumor cells, or inhibiting their growth, by contacting the cells with a fusion protein of a KIM and a toxin or radionuclide, or an anti-KIM ligand antibody conjugated to a toxin or radionuclide.
• the cell may be within a subject, and the protein or the conjugated antibody is administered to the subject.
• Also encompassed within the invention is a method for targeting a toxin or radionuclide to a cell expressing a KIM, comprising contacting the cell with a fusion protein comprising a KIM ligand and a toxin or radionuclide, or an anti-KIM antibody conjugated to a toxin or radionuclide.
• Another embodiment includes the method of suppressing growth of a tumor cell which expresses KIM, comprising contacting the cell with a fusion protein of KIM ligand and a toxin or radionuclide or with an anti-KIM antibody conjugated to a toxin or radionuclide; the cell may be within a subject, and the protein administered to the subject.
• subject used herein is taken to mean any mammal to which KIM may be administered.
• Subjects specifically intended for treatment with the method of the invention include humans, as well as nonhuman primates, sheep, horses, cattle, goats, pigs, dogs, cats, rabbits, guinea pigs, hamsters, gerbils, rats and mice, as well as the organs, tumors, and cells derived or originating from these hosts.
• the KIM genes of the invention are introduced into damaged tissue, or into tissue where stimulated growth is desirable. Such gene therapy stimulates production of KIM protein by the transfected cells, promoting cell growth and/or survival of cells that express the KIM protein.
• a gene coding for a KIM protein may be introduced into a renal target tissue.
• the KIM protein would be stably expressed and stimulate tissue growth, division, or differentiation, or could potentiate cell survival.
• a KIM gene may be introduced into a target cell using a variety of well-known methods that use either viral or non-viral based strategies.
• Non-viral methods include electroporation, membrane fusion with liposomes, high velocity bombardment with DNA-coated microprojectiles, incubation with calcium-phosphate- DNA precipitate, DEAE-dextran mediated transfection, and direct micro-injection into single cells.
• a KIM gene may be introduced into a cell by calcium phosphate coprecipitation (Pillicer et al., Science, 209: 1414-1422 (1980); mechanical microinjection and/or particle acceleration (Anderson et al., Proc. Nat. Acad. Sci.
• liposome based DNA transfer e.g., LIPOFECTIN-mediated transfection- Fefgner et al., Proc. Nat. Acad. Sci., USA, 84: 471-477, 1987; Gao and Huang, Biochim. Biophys. Res. Comm., 179: 280-285, 1991 ; DEAE Dextran-mediated transfection; electroporation (U.S.
• Patent 4,956,288) or polylysine-based methods in which DNA is conjugated to deliver DNA preferentially to liver hepatocytes (Wolff et al., Science, 247: 465-468, 1990; Curiel et al., Human Gene Therapy 3: 147-154, 1992).
• Target cells may be transfected with the genes of the invention by direct gene transfer. See, e.g., Wolff et al., "Direct Gene Transfer Into Moose Muscle In Vivo", Science 247:1465-68, 1990. In many cases, vector-mediated transfection will be desirable. Any of the methods known in the art for the insertion of polynucleotide sequences into a vector may be used. ( See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989; and Ausubel et al., Current Protocols in Molecular Biology, J.
• Promoter activation may be tissue specific or inducible by a metabolic product or administered substance.
• promoters/enhancers include, but are not limited to, the native c-ret ligand protein promoter, the cytomegalo virus immediate-early promoter/enhancer (Karasuyama et al., J. Exp. Med., 169: 13, 1989); the human beta-actin promoter (Gunning et al., Proc. Nat. Acad. Sci.
• MMTV LTR mouse mammary tumor virus long terminal repeat
• MoLV LTR Moloney murine leukemia virus
• RSV Rous sarcoma virus
• HSV herpes simplex virus
• the KIM genes may also be introduced by specific viral vectors for use in gene transfer systems which are now well established. See for example: Madzak et al., J. Gen . Virol., 73: 1533-36, 1992 (papovavirus SV40); Berkner et al., Curr. Top. Microbiol. Immunol., 158: 39-61, 1992 (adenovirus); Hofmann et al., Proc. Natl. Acad. Sci. 92: 10099-10103, 1995 (baculovirus); Moss et al., Curr. Top. Microbiol. Immunol., 158: 25-38, 1992 (vaccinia virus); Muzyczka, Curr. Top. Microbiol.
• Preferred vectors are DNA viruses that include adenoviruses (preferably Ad-2 or Ad-5 based vectors), baculovirus, herpes viruses (preferably herpes simplex virus based vectors), and parvoviruses (preferably "defective" or non-autonomous parvovirus based vectors, more preferably adeno-associated virus based vectors, most preferably AAV-2 based vectors).
• adenoviruses preferably Ad-2 or Ad-5 based vectors
• baculovirus preferably herpes simplex virus based vectors
• parvoviruses preferably "defective" or non-autonomous parvovirus based vectors, more preferably adeno-associated virus based vectors, most preferably AAV-2 based vectors.
• retroviral vectors have been extensively studied and used in a number of gene therapy applications, they are generally unsuited for infecting cells that are not dividing but may be useful in cancer therapy since they only integrate and express their genes in replicating cells. They are useful for sx. vivo approaches and are attractive in this regard due to their stable integration into the target cell genome.
• Adenoviruses are eukaryotic DNA viruses that can be modified to efficiently deliver a therapeutic or reporter transgene to a variety of cell types.
• the general adenoviruses types 2 and 5 Ad2 and Ad5, respectively
• Ad2 and Ad5 are currently being developed for gene therapy of Duchenne Muscular Dystrophy (DMD)and Cystic Fibrosis (CF).
• DMD Duchenne Muscular Dystrophy
• CF Cystic Fibrosis
• Both Ad2 and Ad5 belong to a subclass of adenovirus that are not associated with human malignancies.
• Adenovirus vectors are capable of providing extremely high levels of transgene delivery to virtually all cell types, regardless of the mitotic state.
• High titers (10 13 plaque forming units/ml) of recombinant virus can be easily generated in 293 cells (an adenovirus- transformed, complementation human embryonic kidney cell line: ATCC CRL1573) and cryo- stored for extended periods without appreciable losses.
• the efficacy of this system in delivering a therapeutic transgene in vivo that complements a genetic imbalance has been demonstrated in animal models of various disorders. See Watanabe, Atherosclerosis, 36: 261-268, 1986; Tanzawa et al., FEBS Letters 118(l):81-84, 1980; Golasten et al., New Engl.J. Med. 309:288- 296, 1983; Ishibashi et al., J. Clin.
• recombinant replication defective adenovirus encoding a cDNA for the cystic fibrosis transmembrane regulator has been approved for use in at least two human CF clinical trials. See, e.g., Wilson, Nature 365:691-692 , 1993. Further support of the safety of recombinant adenoviruses for gene therapy is the extensive experience of live adenovirus vaccines in human populations.
• the first-generation recombinant, replication-deficient adenoviruses which have been developed for gene therapy of DMD and other inherited disorders contain deletions of the entire Ela and part of the Elb regions.
• This replication-defective virus is grown in 293 cells containing a functional adenovirus Ela gene which provides a transacting Ela protein.
• El -deleted viruses are capable of replicating and producing infectious virus in the 293 cells, which provide Ela and Elb region gene products in trans.
• the resulting virus is capable of infecting many cell types and can express the introduced gene (providing it carries its own promoter), but cannot replicate in a cell that does not carry the El region DNA unless the cell is infected at a very high multiplicity of infection.
• Adenoviruses have the advantage that they have a broad host range, can infect quiescent or terminally differentiated cells such as neurons, and appear essentially non- oncogenic. Adenoviruses do not appear to integrate into the host genome. Because they exist extrachromasomally, the risk of insertional mutagenesis is greatly reduced. Ali et al., supra, at 373. Recombinant adenoviruses (rAdV) produce very high titers, the viral particles are moderately stable, expression levels are high, and a wide range of cells can be infected. Their natural host cells are airway epithelium, so they are useful for therapy of lung cancers.
• Baculovirus-mediated transfer has several advantages. Baculoviral gene transfer can occur in replicating and nonreplicating cells, and can occur in renal cells, as well as in hepatocytes, neural cells, spleen, skin, and muscle. Baculovirus is non-replicating and nonpathogenic in mammalian cells. Humans lack pre-existing antibodies to recombinant baculovirus which could block infection. In addition, baculovirus is capable of incorporating and transducing very large DNA inserts.
• Adeno-associated viruses have also been employed as vectors for somatic gene therapy.
• AAV is a small, single-stranded (ss) DNA virus with a simple genomic organization (4- 7 kb) that makes it an ideal substrate for genetic engineering.
• Two open reading frames encode a series of rep and cap polypeptides.
• Rep polypeptides rep78, rep68, rep 62 and rep 40
• the cap proteins form the virion capsid.
• ITRs inverted terminal repeats
• the entire rep and cap domains can be excised and replaced with a therapeutic or report r transgene. See B.J. Carter, in Handbook of Parvoviruses, ed., P. Tijsser, CRC Press, pp. 155- 168 (1990). It has been shown mat the ITRs represent the minimal sequence required for replication, rescue, packaging, and integration of the AAV genome.
• Adeno-associated viruses have significant potential in gene therapy.
• the viral particles are very stable and recombinant AAVs (rAAV)have "drug-like" characteristic 1 in that rAAV can be purified by pelleting or by CsCl gradient banding. They are heat stable and can be lyophilized to a powder and rehydrated to full activity.
• rAAV recombinant AAVs
• Their DNA stably integrates into host chromosomes so expression is long-term.
• Their host range is broad and AAV causes no known disease so that the recombinant vectors are non-toxic.
• sequences of interest can be identified by conventional methods such as nucleic acid hybridization using probes comprising sequences that are homologous/complementary to the inserted gene sequences of the vector.
• sequence(s) may be identified by the presence or absence of a "marker" gene function (e.g, thymidine kinase activity, antibiotic resistance, and the like) caused by introduction of the expression vector into the target cell.
• a "marker" gene function e.g, thymidine kinase activity, antibiotic resistance, and the like
• the compounds of the invention are formulated according to standard practice, such as prepared in a carrier vehicle.
• pharmaceutically acceptable carrier means one or more organic or inorganic ingredients, natural or synthetic, with which the mutant proto- oncogene or mutant oncoprotein is combined to facilitate its application.
• a suitable carrier includes sterile saline although other aqueous and non-aqueous isotonic sterile solutions and sterile suspensions known to be pharmaceutically acceptable are known to those of ordinary skill in the art.
• carrier encompasses liposomes and the HIV-1 tat protein (See Chen et al., Anal. Biochem. 227: 168-175, 1995) as well as any plasmid and viral expression vectors.
• any of the novel polypeptides of this invention may be used in the form of a pharmaceutically acceptable salt.
• Suitable acids and bases which are capable of forming salts with the polypeptides of the present invention are well known to those of skill in the art, and include inorganic and organic acids and bases.
• a compound of the invention is administered to a subject in a therapeutically-effective amount, which means an amount of the compound which produces a medically desirable result or exerts an influence on the particular condition being treated.
• An effective amount of a compound of the invention is capable of ameliorating or delaying progression of the diseased, degenerative or damaged condition.
• the effective amount can be determined on an individual basis and will be based, in part, on consideration of the physical attributes of the subject, symptoms to be treated and results sought. An effective amount can be determined by one of ordinary skill in the art employing such factors and using no more than routine experimentation.
• a liposome delivery system for a compound of the invention may be any of a variety of unilamellar vesicles, multilamellar vesicles, or stable plurilamellar vesicles, and may be prepared and administered according to methods well known to those of skill in the art, for example in accordance with the teachings of United States Patent 5,169,637, 4,762,915, 5,000,958 or 5,185,154.
• treatment of human acute renal failure with liposome-encapsulated KIM protein may be performed in vivo by introducing a KIM protein into cells in need of such treatment using liposomes.
• the liposomes can be delivered via catheter to the renal artery.
• the recombinant KIM protein is purified, for example, from CHO cells by immunoaffinity chromatography or any other convenient method, then mixed with liposomes and incorporated into them at high efficiency.
• the encapsulated protein may be tested in vitro for any effect on stimulating cell growth.
• the compounds of the invention may be administered in any manner which is medically acceptable. This may include injections, by parenteral routes such as intravenous, intravascular, intraarterial, subcutaneous, intramuscular, intratumor, intraperitoneal, intraventricular, intraepidural, or others as well as oral, nasal, ophthalmic, rectal, or topical. Sustained release administration is also specifically included in the invention, by such means as depot injections or erodible implants. Localized delivery is particularly contemplated, by such means as delivery via a catheter to one or more arteries, such as the renal artery or a vessel supplying a localized tumor.
• ATC ACA ACG ACA TGT TGG GGC CGG GGG CAA TGC CCA TAT TCT AGT TGT 794 lie Thr Thr Thr Cys Trp Gly Arg Gly Gin Cys Pro Tyr Ser Ser Cys 45 50 55 60
• GAAAGACACC ACATTTTCAA TAATAAATCA GTTTGTCACA ATTAATAAAA TATTTTGTTT 2525 GCTAAGAAGT AAAAAAAAAA AAAAAAAGTC GACGCGGCCG C 2566
• TCT AGT TGT CAA AAT ATA CTT ATT TGG ACC AAT GGA TAC CAA GTC ACC 363 Ser Ser Cys Gin Asn He Leu He Trp Thr Asn Gly Tyr Gin Val Thr 60 65 70
• AAT CAC ACT GTA AGA ATC CCT TTG AGG AAG CCG CAG AGA AAC CCG ACT 843 Asn His Thr Val Arg He Pro Leu Arg Lys Pro Gin Arg Asn Pro Thr 220 225 230
• CAG ATC GCC CAG AAC AGG GTG TGC AGC CCG GTG GCT GTG GAT GAG CTG 1459 Gin He Ala Gin Asn Arg Val Cys Ser Pro Val Ala Val Asp Glu Leu 440 445 450
• GAA ACC CAC CCT ACG ACA CTG CAG GGA GCA ATA AGG AGA GAA CCC ACC 1015 Glu Thr His Pro Thr Thr Leu Gin Gly Ala He Arg Arg Glu Pro Thr 235 240 245

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Immunology (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Molecular Biology (AREA)
• Biomedical Technology (AREA)
• Biochemistry (AREA)
• Cell Biology (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Toxicology (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Urology & Nephrology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• Zoology (AREA)
• Hematology (AREA)
• Gastroenterology & Hepatology (AREA)
• Physics & Mathematics (AREA)
• Food Science & Technology (AREA)
• Analytical Chemistry (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Microbiology (AREA)
• Biotechnology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Optics & Photonics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Peptides Or Proteins (AREA)
• Electrotherapy Devices (AREA)

Priority Applications (24)

Applications Claiming Priority (4)

Related Child Applications (1)

Publications (1)

Family

ID=26690881

Family Applications (1)

Country Status (27)

Cited By (19)

Families Citing this family (34)

Citations (1)

Family Cites Families (20)

• 1997
  • 1997-05-23 HU HU9902770A patent/HU226205B1/hu unknown
  • 1997-05-23 BR BR9709115A patent/BR9709115A/pt not_active Application Discontinuation
  • 1997-05-23 CN CNB971958289A patent/CN1147584C/zh not_active Expired - Lifetime
  • 1997-05-23 TR TR1998/02421T patent/TR199802421T2/xx unknown
  • 1997-05-23 DE DE69735364T patent/DE69735364T3/de not_active Expired - Lifetime
  • 1997-05-23 WO PCT/US1997/009303 patent/WO1997044460A1/en active IP Right Grant
  • 1997-05-23 CA CA2257851A patent/CA2257851C/en not_active Expired - Lifetime
  • 1997-05-23 SK SK1609-98A patent/SK285461B6/sk not_active IP Right Cessation
  • 1997-05-23 AT AT97932145T patent/ATE318903T1/de active
  • 1997-05-23 CZ CZ19983813A patent/CZ295936B6/cs not_active IP Right Cessation
  • 1997-05-23 ES ES97932145T patent/ES2258793T5/es not_active Expired - Lifetime
  • 1997-05-23 IL IL127162A patent/IL127162A/en not_active IP Right Cessation
  • 1997-05-23 NZ NZ336467A patent/NZ336467A/xx not_active IP Right Cessation
  • 1997-05-23 EP EP97932145A patent/EP0907735B9/en not_active Expired - Lifetime
  • 1997-05-23 PL PL97330313A patent/PL188826B1/pl unknown
  • 1997-05-23 SI SI9730732T patent/SI0907735T2/sl unknown
  • 1997-05-23 DK DK97932145.2T patent/DK0907735T5/da active
  • 1997-05-23 EP EP05111979A patent/EP1655367A1/en not_active Withdrawn
  • 1997-05-23 EE EE9800409A patent/EE04817B1/xx unknown
  • 1997-05-23 JP JP54298697A patent/JP4602482B2/ja not_active Expired - Lifetime
  • 1997-05-23 EA EA199801044A patent/EA004402B1/ru not_active IP Right Cessation
  • 1997-05-23 AU AU35676/97A patent/AU712289B2/en not_active Expired
  • 1997-05-23 PT PT97932145T patent/PT907735E/pt unknown
• 1998
  • 1998-11-20 NO NO985427A patent/NO327597B1/no not_active IP Right Cessation
  • 1998-11-20 IS IS4902A patent/IS2636B/is unknown
  • 1998-11-23 US US09/197,970 patent/US6664385B1/en not_active Expired - Lifetime
  • 1998-11-30 BG BG102967A patent/BG64678B1/bg unknown
• 2000
  • 2000-01-21 HK HK00100386A patent/HK1021746A1/xx not_active IP Right Cessation
• 2003
  • 2003-09-04 US US10/655,506 patent/US20050089868A1/en not_active Abandoned
• 2006
  • 2006-08-08 US US11/463,227 patent/US20060286031A1/en not_active Abandoned
  • 2006-08-08 US US11/463,239 patent/US20070141590A1/en not_active Abandoned
• 2007
  • 2007-09-11 JP JP2007236021A patent/JP4316640B2/ja not_active Expired - Lifetime
• 2008
  • 2008-07-18 JP JP2008187615A patent/JP2009039111A/ja not_active Withdrawn
• 2009
  • 2009-03-03 NO NO20090945A patent/NO20090945L/no not_active Application Discontinuation

Patent Citations (1)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events